BC Environmental and Occupational Health Research Network

The Lymphoma Research Foundation’s Mantle Cell Lymphoma Consortium is seeking applications for project planning grants geared toward obtaining larger-scale research support from NIH/NCI (or another major funder). The purpose of these grants is to provide funds for MCL Consortium members and other MCL researchers to develop larger, longer-term proposals that are likely to become successfully funded from other sources, including Program Project Grants such as the POI. Multi-investigator, multi-site and/or multi-disciplinary proposals are particularly encouraged.

The Lymphoma Research Foundation’s Mantle Cell Lymphoma Consortium is seeking applications for project planning grants geared toward obtaining larger-scale research support from NIH/NCI (or another major funder). The purpose of these grants is to provide funds for MCL Consortium members and other MCL researchers to develop larger, longer-term proposals that are likely to become successfully funded from other sources, including Program Project Grants such as the POI. Multi-investigator, multi-site and/or multi-disciplinary proposals are particularly encouraged.

Lymphoma Research Foundation’s Follicular Lymphoma Consortium is seeking proposals for clinical studies in follicular lymphoma. Applications to this initiative must involve either clinical trials, correlative research associated with a clinical trial, or be based on the study of primary follicular lymphoma patient samples.

The goal of this initiative is to stimulate novel investigations into the diagnosis, evaluation, or therapy of follicular lymphoma by providing follicular lymphoma cell suspensions to researchers with innovative ideas. To accomplish this objective, LRF seeks proposals that advance the understanding of the human biology of follicular lymphoma or that verify molecular targets for follicular lymphoma therapeutics.

The Lymphoma Research Foundation’s Chronic Lymphocytic Leukemia Committee for Clinical Trials (CLLCCT) seeks proposals in CLL for translational or clinical studies using novel agents alone or in combination with existing therapies as part of Phase I and Phase II clinical trials being conducted by an institution or institutions with a successful clinical trial track record. Studies including one or more of the following examples are encouraged: pharmacokinetics, pharmacodynamics, pharmacogenomics, molecular diagnostics, etc. Priority of funding will be oriented toward those grants emphasizing inter- or multi-institutional collaboration.